TYK Medicines, Inc (02410.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.2x

Market Cap

HKD 2.32B

MomentumView details →

1D Return

+2.31%

YTD Return

−52.67%

RSI (14)

45.5

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−5.2x

Market Cap

HKD 2.32B

RSI (14)

45.5

MomentumView details →

1D Return

+2.31%

YTD Return

−52.67%

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

40.51%

ROA (TTM)

−80.09%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

−100.00%

EPS CAGR 3Y

+32.17%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−HKD 0.08

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Capital & dividendView details →

Debt/Equity

−0.12x

Current Ratio

0.14x

Quick Ratio

0.14x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−423.91M

Op. CF (TTM)

—

Next earningsApr 1, 2027 →

Latest newsMore news →

TYK Medicines announced that its self-developed innovative drug TY-9591 tablets (deuterated almonertinib mesylate) received conditional marketing approval from China's National Medical Products Administration (NMPA) for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or L858R mutation and central nervous system metastases.8d ago

Tongyuan Kang Medical reported interim results for the six months ended June 2026, with a narrowed loss of 24.9 million RMB compared to a loss of 112 million RMB in the same period last year, no revenue generated, and no dividend declared.18d ago

Similar companies

天目药业600671.SH Organon & Co.OGN Tong Ren Tang Technologies Co. Ltd.01666.HK Impact Therap-b07630.HK Fangzhou Inc.06086.HK 神奇制药600613.SH Find similar companies →

Latest newsMore news →

TYK Medicines announced that its self-developed innovative drug TY-9591 tablets (deuterated almonertinib mesylate) received conditional marketing approval from China's National Medical Products Administration (NMPA) for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or L858R mutation and central nervous system metastases.8d ago Tongyuan Kang Medical reported interim results for the six months ended June 2026, with a narrowed loss of 24.9 million RMB compared to a loss of 112 million RMB in the same period last year, no revenue generated, and no dividend declared.18d ago